Seres Therapeutics Reports Second Quarter Financial Results and Provides Progress Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Seres Therapeutics (MCRB) Tops Q2 EPS by 24c, Revenues Beat
August 6, 2019 8:00 AM EDTSeres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of ($0.24), $0.24 better than the analyst estimate of ($0.48). Revenue for the quarter came in at $12.53 million versus the consensus estimate of $8.13 million.
Four significant microbiome program milestones expected during 2020, including readouts from two late-stage development... More